Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1983 1
1985 2
1986 4
1988 5
1989 3
1990 10
1991 1
1992 7
1993 8
1994 8
1995 6
1996 8
1997 6
1998 8
1999 9
2000 4
2001 1
2002 6
2003 9
2004 7
2005 8
2006 9
2007 9
2008 4
2009 3
2010 4
2011 1
2012 3
2013 3
2014 3
2015 2
2017 2
2018 1
2019 2
2020 3
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 15937318

168 results

Results by year

Filters applied: . Clear all
Page 1
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN, McLendon RE, Bigner DD, Zalutsky MR. Akabani G, et al. J Nucl Med. 2005 Jun;46(6):1042-51. J Nucl Med. 2005. PMID: 15937318 Free article. Clinical Trial.
Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.
Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, Zalutsky MR. Akabani G, et al. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):947-58. doi: 10.1016/s0360-3016(99)00500-3. Int J Radiat Oncol Biol Phys. 2000. PMID: 10705017 Clinical Trial.
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Reardon DA, et al. J Clin Oncol. 2006 Jan 1;24(1):115-22. doi: 10.1200/JCO.2005.03.4082. J Clin Oncol. 2006. PMID: 16382120 Clinical Trial.
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, Herndon JE 2nd, Wikstrand C, Boulton ST, Friedman AH, Bigner DD, Zalutsky MR. McLendon RE, et al. Nucl Med Biol. 2007 May;34(4):405-13. doi: 10.1016/j.nucmedbio.2007.01.009. Epub 2007 Mar 30. Nucl Med Biol. 2007. PMID: 17499730 Free PMC article.
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE 2nd, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR. Bigner DD, et al. J Clin Oncol. 1998 Jun;16(6):2202-12. doi: 10.1200/JCO.1998.16.6.2202. J Clin Oncol. 1998. PMID: 9626222 Clinical Trial.
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE 2nd, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD. Reardon DA, et al. Neuro Oncol. 2008 Apr;10(2):182-9. doi: 10.1215/15228517-2007-053. Epub 2008 Feb 20. Neuro Oncol. 2008. PMID: 18287339 Free PMC article.
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD. Cokgor I, et al. J Clin Oncol. 2000 Nov 15;18(22):3862-72. doi: 10.1200/JCO.2000.18.22.3862. J Clin Oncol. 2000. PMID: 11078500 Clinical Trial.
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Reardon DA, et al. J Clin Oncol. 2002 Mar 1;20(5):1389-97. doi: 10.1200/JCO.2002.20.5.1389. J Clin Oncol. 2002. PMID: 11870184 Clinical Trial.
Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Bigner SH, Zhao XG, Wikstrand CJ, Pegram CN, et al. Bigner DD, et al. J Neurooncol. 1995;24(1):109-22. doi: 10.1007/BF01052668. J Neurooncol. 1995. PMID: 8523067 Clinical Trial.
168 results